Evaxion Biotech A/S : Resignation of Chief Financial Officer; Appointment of Interim Chief Financial Officer - Form 6-K

Published: 2021-10-18 16:42:32 ET EVAX

Resignation of Chief Financial Officer; Appointment of Interim Chief Financial Officer

On October 15, 2021, Glenn S. Vraniak, the Chief Financial Officer of Evaxion Biotech, A/S (the "Company"), informed the Company that effective November 1, 2021, he will be leaving the Company to pursue other opportunities outside the biopharmaceutical industry. In his place, the Company has appointed Mr. Niels Iversen Møller, M.D., as interim Chief Financial Officer, to be effective immediately upon the effective date of Mr. Vraniak's resignation. Mr. Møller was a co-founder of the Company and is currently the Company's Chief Business Officer. In addition to his medical degree, Mr. Moller has a BA in Economics from Copenhagen Business School.

The Company and Mr. Vraniak have agreed that he will continue to act as the Company's Chief Financial Officer on a full time basis until the effective date of his resignation in order to ensure an orderly transition. In addition, Mr. Vraniak has agreed to provide additional transition services beyond the effective date, as needed, including providing assistance in preparing the Company's third quarter financial statements and earnings call.

The Company thanks Mr. Vraniak for his invaluable service as its Chief Financial Officer over the past few years and wishes him well in his new endeavor.

Disclaimer

Evaxion Biotech A/S published this content on 18 October 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 18 October 2021 20:41:10 UTC.